{"id":38648,"date":"2018-08-15T01:00:00","date_gmt":"2018-09-17T06:23:14","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/2018\/09\/17\/%e3%80%90bd-vc%e3%80%91%e5%ba%b7%e5%93%b2%e8%8d%af%e4%b8%9a%e6%8a%95%e8%b5%841000%e4%b8%87%e8%8b%b1%e9%95%91%e5%bc%95%e8%bf%9b%e7%89%b9%e6%af%94%e8%90%98%e8%8a%ac%e7%ba%b3%e7%b1%b3%e5%88%b6%e5%89%82\/"},"modified":"2018-09-17T14:23:19","modified_gmt":"2018-09-17T06:23:19","slug":"%e3%80%90bd-vc%e3%80%91%e5%ba%b7%e5%93%b2%e8%8d%af%e4%b8%9a%e6%8a%95%e8%b5%841000%e4%b8%87%e8%8b%b1%e9%95%91%e5%bc%95%e8%bf%9b%e7%89%b9%e6%af%94%e8%90%98%e8%8a%ac%e7%ba%b3%e7%b1%b3%e5%88%b6%e5%89%82","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/38648\/","title":{"rendered":"\u3010BD\/VC\u3011\u5eb7\u54f2\u836f\u4e1a\u6295\u8d441000\u4e07\u82f1\u9551\u5f15\u8fdb\u7279\u6bd4\u8418\u82ac\u7eb3\u7c73\u5236\u5242"},"content":{"rendered":"
\n

\"\u3010BD\/VC\u3011\u5eb7\u54f2\u836f\u4e1a\u6295\u8d441000\u4e07\u82f1\u9551\u5f15\u8fdb\u7279\u6bd4\u8418\u82ac\u7eb3\u7c73\u5236\u5242\"<\/p>\n

\u5eb7\u54f2\u836f\u4e1a(00867)\u516c\u544a\uff0c\u96c6\u56e2\u901a\u8fc7\u5176\u5168\u8d44\u9644\u5c5e\u516c\u53f8\u4e0eBlueberry Therapeutics Limited\u4e8e<\/span><\/strong>2018\u5e748\u670814\u65e5\u7b7e\u8ba2\u4e86\u8d44\u4ea7\u8d2d\u4e70\u534f\u8bae<\/span><\/strong>\u3002<\/p>\n

Blueberry Therapeutics Limited, (“Blueberry Therapeutics”) a drug discovery and development company focused on developing innovative nanomedicines for difficult to treat skin and nail infections, today announces that it has successfully completed its \u00a310m Series B Fundraising with investment from China Medical Venture Investment (HK) Limited, a wholly owned subsidiary of China Medical System Holdings Limited (“CMS”), and A&B (HK) Company Limited (“A&B”).<\/span><\/strong><\/p>\n

Blueberry Therapeutics will use the net proceeds of the Series B Fundraising to fund its development programme for BB2603 for the treatment of onychomycosis and tinea pedis, as well as progressing its earlier stage acne, topical analgesia and atopic dermatitis programmes.<\/p>\n

\"\u3010BD\/VC\u3011\u5eb7\u54f2\u836f\u4e1a\u6295\u8d441000\u4e07\u82f1\u9551\u5f15\u8fdb\u7279\u6bd4\u8418\u82ac\u7eb3\u7c73\u5236\u5242\"<\/p>\n

\u6839\u636e\u534f\u8bae\uff0c\u96c6\u56e2\u8d2d\u5f97Blueberry Therapeutics\u9886\u5148\u4ea7\u54c1BB2603(\u7528\u4e8e\u6cbb\u7597\u7532\u771f\u83cc\u75c5\u548c\u8db3\u7663)\u7684\u4e2d\u56fd\u3001\u97e9\u56fd\u3001\u671d\u9c9c\u53ca\u8499\u53e4\u7684\u5168\u90e8\u76f8\u5173\u8d44\u4ea7;\u96c6\u56e2\u8fdb\u4e00\u6b65\u83b7\u53d6Blueberry Therapeutics\u5229\u7528\u5176\u72ec\u7279\u7eb3\u7c73\u5236\u5242\u8f93\u9001\u7cfb\u7edf\u5728\u76ae\u80a4\u79d1\u53ca\u5176\u4ed6\u9886\u57df\u6b63\u5728\u5f00\u53d1\u6216\u540e\u7eed\u5f00\u53d1\u7684\u5176\u4ed6\u7ba1\u7ebf\u4ea7\u54c1(\u5982\u7528\u4e8e\u6cbb\u7597\u7279\u5e94\u6027\u76ae\u708e\u3001\u75e4\u75ae\u7b49\u65b9\u9762\u7684\u4ea7\u54c1)\u7684\u533a\u57df\u5185\u5168\u90e8\u76f8\u5173\u8d44\u4ea7\u7684\u6743\u5229\u3002<\/span><\/p>\n


<\/p>\n

\u4e0a\u8ff0\u8d44\u4ea7\u5177\u4f53\u5305\u62ec\u4f46\u4e0d\u9650\u4e8e\u6240\u6709\u533a\u57df\u5185\u7684\u5173\u4e8e\u4ea7\u54c1\u7814\u53d1\u3001\u5546\u4e1a\u5316\u53ca\u751f\u4ea7\u65b9\u9762\u7684\u56fd\u5bb6\u4e13\u5229\u3001\u56fd\u5bb6\u5546\u6807\u53ca\u5fc5\u8981\u7684\u6ce8\u518c\u8bb8\u53ef\u7b49\u3002\u53e6\u5916\uff0c\u6839\u636e\u534f\u8bae\u96c6\u56e2\u8fd8\u83b7\u5f97\u4e0e\u6b64\u6b21\u4ea4\u6613\u6709\u5173\u7684\u6240\u6709\u5fc5\u8981\u8bb8\u53ef\u3002<\/p>\n


<\/p>\n

BB2603\u662f\u4e00\u79cd\u91c7\u7528\u4e86\u7eb3\u7c73\u6280\u672f\u7684\u65b0\u578b\u76ae\u80a4\u55b7\u96fe\u5242\uff0c\u7528\u65bc\u6cbb\u7597\u7532\u771f\u83cc\u75c5\u548c\u8db3\u7663\uff0c\u6b63\u5728\u5fb7\u56fd\u8fdb\u884cI\/II\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8ba1\u5212\u5728\u7f8e\u56fd\u3001\u6b27\u6d32\u5f00\u5c55\u2162\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u5e76\u5df2\u5728\u4e2d\u56fd\u7533\u8bf7\u5236\u5242\u4e13\u5229\u4fdd\u62a4\u3002<\/p>\n


<\/p>\n

Blueberry Therapeutics\u7684\u7eb3\u7c73\u5236\u5242\u8f93\u9001\u7cfb\u7edf\u662f\u4e00\u4e2a\u521b\u65b0\u7684\u4e13\u5229\u836f\u7269\u6280\u672f\u5e73\u53f0\uff0c\u53ef\u5feb\u901f\u7ec4\u88c5\u5c0f\u5206\u5b50\u548c\u5927\u5206\u5b50(\u4f8b\u5982\u86cb\u767d\u8d28\u3001\u80bd\u548c\u6838\u9178)\uff0c\u5e76\u5c06\u5176\u201c\u5305\u88c5\u201d\u6210\u7eb3\u7c73\u9897\u7c92\u3002Blueberry Therapeutics\u6210\u7acb\u4e8e2011\u5e7411\u6708\uff0c\u662f\u4e00\u5bb6\u836f\u7269\u53d1\u73b0\u548c\u5f00\u53d1\u516c\u53f8\uff0c\u81f4\u529b\u4e8e\u5f00\u53d1\u521b\u65b0\u7684\u7eb3\u7c73\u836f\u7269\uff0c\u7528\u4e8e\u6cbb\u7597\u96be\u6cbb\u7684\u76ae\u80a4\u548c\u6307\u7532\u611f\u67d3\u3002<\/p>\n

Dr. John Ridden, Chief Executive Officer of Blueberry Therapeutics said<\/em><\/strong>:<\/em><\/span> “I am delighted to have completed the Series B Fundraising which enables us to progress all of our programmes to the next stages of development. In addition, I got to know the CMS team well during negotiations and I firmly believe they are the ideal partner to help us develop and commercialise our products in the Asia region and we look forward to working closely with them.”<\/em><\/p>\n

Mr. Lam Kong, Chairman, Chief Executive and President of CMS<\/em>, commented:<\/em><\/strong><\/span> “We are very pleased to be shareholders in Blueberry Therapeutics and to be able to support the management team in its quest to deliver high value innovative medicines for patients suffering from a range of dermatological disorders and we look forward to collaborating in the development of the Company’s products.”<\/em><\/p>\n

\"\u3010BD\/VC\u3011\u5eb7\u54f2\u836f\u4e1a\u6295\u8d441000\u4e07\u82f1\u9551\u5f15\u8fdb\u7279\u6bd4\u8418\u82ac\u7eb3\u7c73\u5236\u5242\"<\/p>\n


<\/p>\n

\u5eb7\u54f2\u836f\u4e1a\u8fd1\u671f\u52a8\u4f5c\u9891\u9891<\/strong><\/span><\/p>\n

\"\u3010BD\/VC\u3011\u5eb7\u54f2\u836f\u4e1a\u6295\u8d441000\u4e07\u82f1\u9551\u5f15\u8fdb\u7279\u6bd4\u8418\u82ac\u7eb3\u7c73\u5236\u5242\"<\/strong><\/p>\n

    2018\u5e747\u670831\u65e5\u5eb7\u54f2\u836f\u4e1a\u53d1\u5e03\u516c\u544a\uff0c\u96c6\u56e2\u901a\u8fc7\u5176\u5168\u8d44\u9644\u5c5e\u516c\u53f8\u4e0eActicor Biotech\u7b7e\u8ba2\u4e86\u8d44\u4ea7\u8f6c\u8ba9\u548c\u8bb8\u53ef\u534f\u8bae\u3002\u901a\u8fc7\u534f\u8bae\uff0c\u96c6\u56e2\u4eceActicor Biotech\u8d2d\u5f97\u5176\u4ea7\u54c1ACT017\u53ca\u4ee5\u76f8\u540c\u5316\u5408\u7269\u4e3a\u57fa\u7840\u5f00\u53d1\u7684\u540e\u7eed\u4ea7\u54c1\u7684\u4e2d\u56fd(\u5305\u62ec\u9999\u6e2f\u7279\u522b\u884c\u653f\u533a\u3001\u6fb3\u95e8\u7279\u522b\u884c\u653f\u533a\u548c\u53f0\u6e7e)\u3001\u65b0\u52a0\u5761\u3001\u83f2\u5f8b\u5bbe\u3001\u97e9\u56fd\u3001\u9a6c\u6765\u897f\u4e9a\u7b49\u4e9a\u6d32\u6307\u5b9a\u56fd\u5bb6(\u4e0d\u542b\u65e5\u672c\u3001\u5370\u5ea6\u548c\u897f\u4e9a\u56fd\u5bb6)\u7684\u5168\u90e8\u76f8\u5173\u8d44\u4ea7\uff0c\u8d44\u4ea7\u5177\u4f53\u5305\u62ec\u4f46\u4e0d\u9650\u4e8e\u533a\u57df\u5185\u7684\u6240\u6709\u7684\u6280\u672f\u8bc0\u7a8d\u3001\u77e5\u8bc6\u4ea7\u6743\u6216\u77e5\u8bc6\u4ea7\u6743\u7533\u8bf7\u6743\u3001\u5fc5\u8981\u7684\u6ce8\u518c\u8bb8\u53ef\u3001\u4e13\u5c5e\u4e8e\u533a\u57df\u7684\u6587\u4ef6\u3001\u6863\u6848\u3001\u6570\u636e\u6216\u4fe1\u606f\u53ca\u5176\u4ed6\u7528\u4e8e\u7814\u53d1\u3001\u6ce8\u518c\u3001\u751f\u4ea7\u548c\u5546\u4e1a\u5316\u4ea7\u54c1\u7684\u5fc5\u8981\u6743\u5229\u3002\u53e6\u5916\uff0c\u6839\u636e\u534f\u8bae\u96c6\u56e2\u8fd8\u83b7\u5f97\u4e0e\u8be5\u6b21\u4ea4\u6613\u6709\u5173\u7684\u6240\u6709\u5fc5\u8981\u8bb8\u53ef\u3002\u96c6\u56e2\u76f8\u4fe1\u4ea7\u54c1\u4e8e\u533a\u57df\u4e0a\u5e02\u540e\u5c06\u62e5\u6709\u5e7f\u9614\u7684\u5e02\u573a\u524d\u666f\uff0c\u901a\u8fc7\u6b64\u6b21\u5408\u4f5c\uff0c\u96c6\u56e2\u5c06\u52a0\u5feb\u5f15\u8fdb\u4e13\u5229\u521b\u65b0\u4ea7\u54c1\u7684\u6b65\u4f10\uff0c\u4e3a\u672a\u6765\u53d1\u5c55\u79ef\u7d2f\u4e30\u5bcc\u7684\u4ea7\u54c1\u50a8\u5907\u3002
<\/p>\n

\u3000\u3000\u636e\u6089\uff0cACT017\u662f\u9ad8\u4eb2\u548c\u529b\u4eba\u6e90\u5316\u6297\u4f53\u7247\u6bb5(Fab)\u3001\u8840\u5c0f\u677f\u7cd6\u86cb\u767dVI(GPVI)\u6291\u5236\u5242\uff0c\u5f00\u53d1\u7528\u4e8e\u6025\u6027\u7f3a\u8840\u6027\u8111\u5352\u4e2d\u7684\u6cbb\u7597\uff0c\u4f5c\u4e3a\u6eb6\u6813\u548c\u8840\u6813\u5207\u9664\u672f\u7684\u9644\u52a0\u7597\u6cd5\u6216\u4f5c\u4e3a\u4e0d\u9002\u5408\u6eb6\u6813\u6cbb\u7597\u7684\u60a3\u8005\u7684\u72ec\u7acb\u6cbb\u7597\u65b9\u6848\u3002ACT017\u901a\u8fc7\u9759\u8109\u6ce8\u5c04\u7ed9\u836f\uff0c\u80fd\u591f\u5feb\u901f\u8d77\u6548;\u534a\u8870\u671f\u77ed\uff0c\u4e0d\u6613\u5728\u4f53\u5185\u9020\u6210\u836f\u7269\u84c4\u79ef\u3002ACT017\u7684\u7269\u8d28\u4e13\u5229\u5df2\u901a\u8fc7PCT\u56fd\u9645\u7533\u8bf7\u9014\u5f84\u8fdb\u5165\u4e2d\u56fd\u5e76\u5df2\u516c\u5f00\uff0c\u5982\u83b7\u6388\u6743\uff0c\u4fdd\u62a4\u671f\u9650\u5c06\u81f32036\u5e74\u3002<\/p>\n

\"\u3010BD\/VC\u3011\u5eb7\u54f2\u836f\u4e1a\u6295\u8d441000\u4e07\u82f1\u9551\u5f15\u8fdb\u7279\u6bd4\u8418\u82ac\u7eb3\u7c73\u5236\u5242\"<\/p>\n

    2018\u5e748\u67086\u65e5\uff0c<\/span>\u5eb7\u54f2\u836f\u4e1a\u516c\u5e03\uff0c\u96c6\u56e2\u901a\u8fc7\u5176\u5168\u8d44\u9644\u5c5e\u516c\u53f8\u4e0eCan-Fite BioPharma Ltd.\u7b7e\u8ba2\u4e86\u8bb8\u53ef\u3001\u5408\u4f5c\u4e0e\u7ecf\u9500\u534f\u8bae\u3002\u6839\u636e\u8be5\u534f\u8bae\u7684\u7ea6\u5b9a\uff0c\u96c6\u56e2\u901a\u8fc7\u5176\u5168\u8d44\u9644\u5c5e\u516c\u53f8\u4eceCan-Fite BioPharma\u83b7\u5f97\u4e86\u5176\u73b0\u6709\u4ea7\u54c1CF101\uff08Piclidenoson\uff09<\/strong><\/span>\u53caCF102\uff08Namodenoson\uff09<\/strong><\/span>\u5728\u4e2d\u56fd(\u5305\u62ec\u9999\u6e2f\u7279\u522b\u884c\u653f\u533a\u3001\u6fb3\u95e8\u7279\u522b\u884c\u653f\u533a\u548c\u53f0\u6e7e)\u7684\u72ec\u5bb6\u3001\u6c38\u4e45\u3001\u53ef\u8f6c\u8ba9\u3001\u53ef\u5206\u8bb8\u53ef\u7684\u7814\u53d1\u3001\u6ce8\u518c\u3001\u751f\u4ea7\u548c\u5546\u4e1a\u5316\u4ea7\u54c1\u7684\u6743\u5229\u3002\u5176\u4e2d\uff0c\u96c6\u56e2\u83b7\u8bb8\u53ef\u7684\u4ea7\u54c1\u4e3b\u8981\u9002\u5e94\u75c7\u5206\u522b\u662f\uff1aCF101\u4e3a\u7c7b\u98ce\u6e7f\u6027\u5173\u8282\u708e(RA)\u53ca\u94f6\u5c51\u75c5\uff0cCF102\u4e3a\u809d\u7ec6\u80de\u764c(HCC)\u53ca\u975e\u9152\u7cbe\u6027\u8102\u80aa\u6027\u809d\u75c5(NAFLD)\/\u975e\u9152\u7cbe\u6027\u8102\u80aa\u6027\u809d\u708e(NASH)\u3002<\/p>\n

Upfront and milestone payments total up to <\/em>$74.5M<\/em> plus double-digit royalties.<\/em><\/span><\/strong><\/p>\n

CMS will be responsible for the development, registration and marketing of the drugs in China.<\/em><\/span><\/strong><\/p>\n

Under the terms of the agreement, CMS Medical is making an upfront payment of <\/em>$2,000,000<\/strong> <\/em><\/span>to Can-Fite and is required to pay to Can-Fite milestone payments of up to <\/em>$14,000,000<\/strong><\/em><\/span> upon the achievement of certain regulatory milestones and payments of up to <\/em>$58,500,000 <\/strong><\/em><\/span>upon the achievement of certain sales milestones. In addition, the agreement provides for double-digit royalty payments on net sales.<\/em><\/p>\n

\u3000\u3000\u6b64\u6b21\u5408\u4f5c\u8fdb\u4e00\u6b65\u4e30\u5bcc\u4e86\u96c6\u56e2\u7684\u4e13\u5229\u521b\u65b0\u50a8\u5907\u4ea7\u54c1\u79cd\u7c7b\uff0c\u76f8\u4fe1\u4ea7\u54c1\u4e8e\u533a\u57df\u4e0a\u5e02\u540e\u5c06\u62e5\u6709\u5e7f\u9614\u7684\u5e02\u573a\u524d\u666f\u3002<\/p>\n

\u3000\u3000 Can-Fite BioPharma\u662f\u4e00\u5bb6\u4e34\u5e8a\u9636\u6bb5\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\uff0c\u5f00\u53d1\u7528\u4e8e\u6cbb\u7597\u81ea\u8eab\u514d\u75ab\u6027\u708e\u75c7\u3001\u80bf\u7624\u548c\u809d\u810f\u75be\u75c5\u4ee5\u53ca\u6027\u529f\u80fd\u969c\u788d\u7684\u5c0f\u5206\u5b50\u6cbb\u7597\u4ea7\u54c1\u3002<\/p>\n


<\/p>\n

\u6d3b\u52a8\u9884\u544a\uff1a<\/strong><\/span><\/p>\n

\"\u3010BD\/VC\u3011\u5eb7\u54f2\u836f\u4e1a\u6295\u8d441000\u4e07\u82f1\u9551\u5f15\u8fdb\u7279\u6bd4\u8418\u82ac\u7eb3\u7c73\u5236\u5242\"<\/p>\n

\"\u3010BD\/VC\u3011\u5eb7\u54f2\u836f\u4e1a\u6295\u8d441000\u4e07\u82f1\u9551\u5f15\u8fdb\u7279\u6bd4\u8418\u82ac\u7eb3\u7c73\u5236\u5242\"<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

\u5eb7\u54f2\u836f\u4e1a(00867)\u516c\u544a\uff0c\u96c6\u56e2\u901a\u8fc7\u5176\u5168\u8d44\u9644\u5c5e\u516c\u53f8\u4e0eBlueberry Therapeutics Limite […]<\/p>\n","protected":false},"author":1,"featured_media":38649,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/38648"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=38648"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/38648\/revisions"}],"predecessor-version":[{"id":38657,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/38648\/revisions\/38657"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/38649"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=38648"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=38648"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=38648"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}